Aesica Successfully Introduces Serialization Services at Italian Site
News Apr 17, 2014

Aesica has announced that it has successfully introduced serialization services and initiated commercial production of two anti-allergy product lines for the Chinese market at its Pianezza site, Italy for a global, multinational client.
The packaging lines and associated serialization services are for the dedicated supply for one of Aesica’s strategic partners. The implementation took under six months to complete, with the first production of serialization batches just commenced.
The joint collaboration enabled the skills and unique knowledge of Aesica personnel at Pianezza to deliver serialization packaging methods and processes that fully comply with stringent State Food and Drug Administration regulations set by the Ministry of Health of China and dovetailed with the partners coding requirements. As a consequence of the partnership, Pianezza is one of the first CDMOs in Italy to have successfully implemented serialization for a pharmaceutical product.
The serialization technology uses special digital techniques to check the linear barcode 128 and 20 digit serialized numbers. The code check is in full compliance with international ISO 15416 standards. The check system provides a reliable instrument for checking products and batches all the way through the packaging and distribution process.
The platform has capability for both thermal transfer and thermal ink jet printers for printing stickers with e-codes and variable data with 2D bar codes respectively.
High quality variable programming, inks suitable for a multiplicity of applications and ribbons that comply with the latest legislative and environmental standards have all been part of the installation.
Paolo Pizzorni, Senior Director at Aesica Pianezza commented; “We are delighted that our strategic partnership model has seen the successful development of two robust serialization packaging lines. For our customer this means improved patient safety with a reduced risk of competition from counterfeit products and the ability to detect expired drugs automatically. The end-users are now able to verify the integrity and authenticity of the products dispensed to patients using a simple scan.”
He continued: “China is a key geographic market that Western pharma companies seek to export to. At Aesica we are delighted to be providing serialization services to enable one of our customers to meet the technical and complex serialization regulations in this market.”
RELATED ARTICLES
PhoreMost and Plexxikon Collaborate to Identify Novel Drug Targets
NewsPhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.
READ MORELonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in Texas
NewsFirst-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.
READ MOREIONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE Antibodies
NewsThe project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.
READ MOREComments | 0 ADD COMMENT
To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE2nd International Conference and Exhibition on Nanomedicine and Drug Delivery
May 21 - May 23, 2018
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018
Login
You must be logged in to post a comment.